'Plausible Mechanism' Pathway for Rare-Disease Drugs

In his resignation text to President Trump, Dr. Marty Makary claimed that as FDA Commissioner he had “introduced a new ‘plausible mechanism’ pathway for rare disease drugs,” intended to speed approvals for ultra-rare conditions where full traditional trial evidence may be hard to assemble. The claim was reported by STAT in its coverage of the resignation text.

Independent verification of the pathway’s formal implementation is limited. Critics, including a Health Affairs analysis, have argued that many of Makary’s claimed reforms did not advance much past the announcement stage, casting doubt on how much of the “plausible mechanism” pathway was actually operational before his departure on May 12, 2026.

The page treats this initiative as Makary claimed it — a reform he said he introduced — while noting the thin independent confirmation. Whether acting commissioner Kyle Diamantas or nominee Heidi Overton will pursue any such pathway remains to be seen.

Timeline

• 2025–2026 (claimed): Makary says he introduced a “plausible mechanism” pathway for rare-disease drugs during his commissionership.
• May 12, 2026: Makary resigns; his resignation text to President Trump cites the pathway among his accomplishments, per STAT reporting.
• 2026: Health Affairs and other critics argue many of Makary’s claimed reforms advanced little beyond announcements; formal implementation of this pathway is unverified.